Sjogren Syndrome Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about Sjogren Syndrome clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Phase 4

TREATMENT OF VAGINAL DRYNESS IN SJÖGREN'S DISEASE WITH CO2-LASER VERSUS TOPICAL PROMESTRIENE

Sjogren SyndromeSjogren DiseasePrimary Sjogren Syndrome
University of Sao Paulo General Hospital60 enrolled1 locationNCT07153276
Recruiting
Phase 2

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

SclerodermaRheumatoid Arthritis (RA)Sjogren Syndrome+6 more
Artiva Biotherapeutics, Inc.90 enrolled26 locationsNCT06991114
Recruiting

Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients

Solid TumorsSjogren SyndromeImmune-related Adverse Events+3 more
Hospital Universitario Araba300 enrolled1 locationNCT07249060
Recruiting
Phase 1Phase 2

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases

Sjogren SyndromeSystemic Lupus ErthematosusSystemic Sclerosis (SSc)+3 more
Peking University Third Hospital9 enrolled1 locationNCT06828042
Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Multiple Endocrine Neoplasia Type 1Multiple Endocrine Neoplasia Type 2Rare Disorders+337 more
Sanford Health20,000 enrolled2 locationsNCT01793168
Recruiting
Phase 2

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Systemic Lupus ErythematosusSjogren SyndromeInflammatory Myopathy+6 more
Peking University People's Hospital50 enrolled1 locationNCT06794008
Recruiting
Not Applicable

Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases

Rheumatoid ArthritisConnective Tissue DiseasesDermatomyositis+3 more
Oslo University Hospital218 enrolled1 locationNCT06732674
Recruiting

Rare AutoImmune SElf-management Programme Development

Sjogren SyndromeSystemic Lupus ErthematosusSystemic Sclerosis (SSc)+3 more
University of the West of England360 enrolled1 locationNCT06642870